Register Now - Unlocking Longitudinal Patient-Reported Outcomes: The Untapped Value of Specialty Pharmacyocking
|Articles|December 16, 2005

TOPRA confirms appointment of European Commission official to Advisory Council

Mr. Nils Behrndt, Deputy Head of Unit, Directorate F2 (Pharmaceuticals), DG Enterprise and Industry, European Commission has agreed to join the TOPRA Advisory Council.

TOPRA received yet another endorsement of its leading role in the global regulatory affairs industry. Mr. Nils Behrndt, Deputy Head of Unit, Directorate F2 (Pharmaceuticals), DG Enterprise and Industry, European Commission has agreed to join the TOPRA Advisory Council.

Mr. Behrndt has enjoyed an illustrious career at the European Commission, previously serving as the Acting Head of the Directorate F2. Mr. Behrndt has served the Commission since 2000 as a lawyer and advisor. Previously, he served as a lawyer and researcher for a variety of organisations and entities within Germany. He holds law degrees from Germany and the United Kingdom as well as having a Ph.D. in public administration and law.

TOPRA's President, Margareth Jorvid said, "We are delighted that Nils has joined our ranks. TOPRA will benefit immensely from his guidance and technical expertise offered through our Advisory Council."

Ms. Jorvid went onto say, "I think that this appointment really shows the maturity of our organisation and our expanding appeal worldwide, but most especially within the European Union. We are proud to have such a high-ranking official from the European Commission join TOPRA's Advisory Council."

TOPRA members are currently drawn from 52 countries.


Related to this article

Where AI Leads in Trial Design—and Where Humans Still Need To
In this video interview, Claire Riches, VP of clinical solutions at Citeline, makes the case for AI as a sophisticated strategic advisor in trial design while arguing that humans must remain in the lead—especially when factors the model can't fully account for are at stake.